Literature DB >> 373773

Pharmacokinetics of sodium valproate in dog and mouse.

W Löscher, H Esenwein.   

Abstract

The pharmacokinetics of sodium di-n-propyl-acetate (sodium valproate, Ergenyl) after i.v. and oral administration in dogs and mice were studied. After i.v. administration of 20 and 40 mg/kg sodium valproate in dogs a biphasic exponential decay of valproate serum concentrations was found, so that a two-compartment open model could be assumed. With mice a monophasic exponential decay of valproate serum concentrations was found after i.v. administration of 200 and 420 mg/kg sodium valproate corresponding to a one-compartment open model. Valproate was rapidly eliminated in both species, the half-life being 90--120 min in dogs (T0.5 beta) and 50 min in mice. After oral administration, valproate was readily absorbed in both species. The transfer of valproate from blood to brains of mice was likewise rapid, and the observed concentrations in brain were 1/4 to 1/5 of that in serum. The binding of valproate to serum proteins determined in dog serum was calculated to 88%. The pKa of valproate was determined to 4.56 and valproate is, therefore, nearly lipid-insoluble at pH 7.4.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 373773

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

1.  Analysis of animal pharmacokinetic data: performance of the one point per animal design.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

Review 2.  Methodological aspects of the evaluation of the binding of drugs to plasma and tissue proteins.

Authors:  J P Tillement; E Albengres; S Urien
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

3.  Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.

Authors:  K Badir; A Haj-Yehia; T B Vree; E van der Kleijn; M Bialer
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

4.  Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.

Authors:  G M Pollack; K L Brouwer
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

5.  The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice.

Authors:  Geoffrey J Markowitz; Shilpa D Kadam; Dawn M Boothe; Natasha D Irving; Anne M Comi
Journal:  Neuroreport       Date:  2010-04-21       Impact factor: 1.837

Review 6.  Dogs as a Natural Animal Model of Epilepsy.

Authors:  Wolfgang Löscher
Journal:  Front Vet Sci       Date:  2022-06-22

7.  Mapping a chromosomal locus for valproic acid-induced exencephaly in mice.

Authors:  Yunxia Wang Lundberg; Robert M Cabrera; Kimberly A Greer; Jian Zhao; Rohit Garg; Richard H Finnell
Journal:  Mamm Genome       Date:  2004-05       Impact factor: 2.957

8.  Enzyme cytochemistry combined with electron microscopy, pharmacokinetics, and clinical chemistry for the evaluation of the effects of steady-state valproic acid concentrations on the mouse.

Authors:  R Graf; R Gossrau; H J Merker; R Schwabe; R Stahlmann; H Nau
Journal:  Histochemistry       Date:  1985

9.  Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders.

Authors:  H M Emrich; D von Zerssen; W Kissling; H J Möller; A Windorfer
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1980

10.  Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest.

Authors:  Manoj K Mishra; Claude A Beaty; Wojciech G Lesniak; Siva P Kambhampati; Fan Zhang; Mary A Wilson; Mary E Blue; Juan C Troncoso; Sujatha Kannan; Michael V Johnston; William A Baumgartner; Rangaramanujam M Kannan
Journal:  ACS Nano       Date:  2014-02-19       Impact factor: 15.881

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.